Airspan Networks Holdings Inc Azioni (OTC: MIMOQ)

Ultime notizie per Airspan Networks Holdings Inc (OTC:MIMOQ) Azioni

Airspan Networks Holdings Inc

<a href="https://www.youtube.com/watch?v=0lVi_OBmQd4">https://www.youtube.com/watch?v=0lVi_OBmQd4</a>

News

General

President Trump Says Depends On China How Soon Tariffs Can Come Down

STEL

Stellar Bancorp Announces $65M Share Repurchase Program

ESSA Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESSA#NASDAQ">ESSA</a>) reported quarterly earnings of $0.29 per share. This is a 39.58 percent decrease over earnings of $0.48 per share from the same period last year. The company reported $16.23 million in sales this quarter. This is a 3.74 percent decrease over sales of $16.86 million the same period last year.

Earnings

ESSA

ESSA Bancorp Q2 EPS $0.29 Down From $0.48 YoY, Sales $16.23M Down From $16.86M YoY

Northfield Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFBK#NASDAQ">NFBK</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.18 by 5.56 percent. This is a 26.67 percent increase over earnings of $0.15 per share from the same period last year.

Earnings Beats

NFBK

Northfield Bancorp Q1 EPS $0.19 Beats $0.18 Estimate

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 15 years by 8.62% on an annualized basis producing an average annual return of 19.05%. Currently, UnitedHealth Group has a market capitalization of $389.54 billion. 
Buying $100 In UNH: If an investor had bought $100 of UNH stock 15 years ago, it would be worth $1,405.91 today based on a price of $427.96 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745443826_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 15 Years

Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) is looking for Q2 Adj EPS of $1.15-$1.65 vs $2.54 analyst estimate..

Guidance

Alaska Air Gr Sees Q2 Adj EPS $1.15-$1.65 vs $2.54 Est

Biotech

MLYS

Mineralys Therapeutics Reveals Publication Of Pivotal Phase 2 Advance-HTN Results In The New England Journal Of Medicine

Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.74) by 4.05 percent. This is a 16.3 percent increase over losses of $(0.92) per share from the same period last year. The company reported quarterly sales of $3.14 billion which missed the analyst consensus estimate of $3.17 billion by 1.16 percent. This is a 40.55 percent increase over sales of $2.23 billion the same period last year.

Earnings Misses

Alaska Air Gr Q1 Adj. EPS $(0.77) Misses $(0.74) Estimate, Sales $3.14B Miss $3.17B Estimate

Marvell Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) on Wednesday&nbsp;announced the successful interoperability of the&nbsp;Marvell Structera&nbsp;portfolio of Compute Express Link&nbsp;(CXL) devices&nbsp;with Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) EPYC CPUs and&nbsp;5th&nbsp;Gen Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44948063/marvell-announces-successful-interoperability-of-structera-cxl-portfolio-with-amd-epyc-cpu-and-5th" rel="noreferrer noopener">Intel Xeon platforms</a>.
The move marks Marvell&#8217;s progress towards an open and interoperable CXL ecosystem, which will address the growing demands for memory bandwidth and capacity in next-generation cloud data centers.
Marvell tapped AMD and Intel to extensively test Structera CXL products with AMD EPYC and 5th&nbsp;Gen Intel Xeon Scalable platforms across various configurations, workloads, and operating conditions.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44653936/broadcom-and-marvell-poised-for-growth-as-nvidias-cpo-push-faces-delays-analyst-reveals" rel="noreferrer noopener">Rising Tide Of AI Is So Strong That Semiconductor Optical Industry Projects $30 Billion Total Addressable Market By 2029</a>
The results demonstrated seamless interoperability, delivering stability, scalability, and high-performance memory expansion that cloud data center providers need for mass deployment.
The first-quarter&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44852860/nvidia-lam-research-and-marvell-to-face-least-impact-from-tariffs-while-intel-and-arm-could-suffer-more-bofa-analyst'" rel="noreferrer noopener">semiconductor earnings procession</a> kicked off with&nbsp;ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) last Wednesday&nbsp;and Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a target="_blank" href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" rel="noreferrer noopener">on Thursday</a>.
For U.S. chip vendors,&nbsp;BofA Securities&nbsp;analysts Vivek Arya and Duksan Jang expect first-quarter results to beat as their original outlook was likely conservative and tariff-related pull-ins created a better demand environment. However, the second-quarter outlook could be in line as companies could widen the guidance range.
Marvell stock plunged over 55% year-to-date. Marvell&#8217;s <a target="_blank" href="https://www.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst" rel="noreferrer noopener">exit from the</a> auto space follows its October quarter restructuring, where it began shifting investments away from enterprise networking, carrier infrastructure, and automotive.
The company is now focused on AI and accelerated computing, a theme JPMorgan&#8217;s&nbsp;Harlan Sur sees as key to unlocking long-term value.
Price Action: MRVL stock closed higher by 6.22% to $53.77 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44903362/american-express-solid-revenue-and-spending-trends-drive-analyst-optimism" target="_blank" rel="noreferrer noopener">American Express&#8217; Solid Revenue, Spending Trends Drive Analyst Optimism</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Movers

Tech

ASML

INTC

MRVL

What's Going On With Marvell Technology Stock On Wednesday?

Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/04/b44965025/discover-financial-services-reports-first-quarter-2025-net-income-of-1-1-billion-or-4-25-per-dilut">details from the quarter.  </a>
The Details: Discover reported quarterly earnings of $4.25 per share, which beat the analyst consensus estimate of $3.39 by 25.37%. Quarterly revenue came in at $4.25 billion, which beat the analyst consensus estimate of $4.22 billion and is an increase over revenue of $4.21 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, Discover reported:
<ul>
<li>Digital Banking pretax income of $1.4 billion for the quarter was $316 million higher than the prior year period. </li>
<li>Total loans ended the quarter at $117.4 billion, down 7% year-over-year as a result of the student loan sale, and down 3% sequentially due to seasonal trends.</li>
<li>Net interest income for the quarter increased $71 million year-over-year, or 2%, driven by net interest margin expansion. </li>
<li>Net interest margin was 12.18%, up 115 basis points versus the prior year, benefiting from the student loan sale.</li>
<li>Non-interest income increased $15 million, or 3% from the prior year period primarily due to higher net discount and interchange revenue.</li>
<li>The total net charge-off rate was 4.99%, up seven basis points from the prior year period. Excluding the impact of the student loan sale, the net charge-off rate would have declined.</li>
<li>Provision for credit losses of $1.2 billion decreased $253 million from the prior year quarter, driven by a $190 million favorable reserve change and a $97 million decrease in net charge-offs.</li>
<li>Payment Services pretax income of $91 million was up $9 million year-over-year, or 11% primarily due to volume growth in PULSE and Diners Club as well as lower expenses.</li>
</ul>
&#8220;Discover&#8217;s solid first quarter financial performance benefited from a strong net interest margin and positive credit trends,&#8221; said Michael Shepherd, Discover&#8217;s Interim CEO. 
&#8220;These results reflect our good execution and the strength of our business model. We are pleased that Capital One has received all required approvals and look forward to completing our merger.&#8221;
The company confirmed that it expects the merger with Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) to close on or about May 18, 2025.
DFS Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Discover stock closed Wednesday up 3.63% at $176.46.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Discover Financial Reports Better-Than-Expected Q1, Expects Capital One Merger To Close In May

HOMB

Home BancShares Increased Quarterly Cash Dividend From $0.195  To $0.2

ASGN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) is looking for Q2 GAAP EPS of $0.66-$0.78 vs $0.92 analyst estimate..

ASGN

ASGN Sees Q2 GAAP EPS $0.66-$0.78 vs $0.92 Est

IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares gained on Wednesday. The company unveiled a distribution agreement with Toyota Tsusho Corporation, marking the company&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44945326/ionq-signs-historic-agreement-with-toyota-tsusho-corporation-to-advance-quantum-computing-opportun" rel="noreferrer noopener">official entry into the Japanese market</a>.
The partnership, revealed during the Shanghai International Automobile Industry Exhibition, is set to fast-track the adoption of quantum computing technologies in Japan by leveraging Toyota Tsusho&#8217;s deep commercial networks and tech-forward positioning.
Niccolo de Masi, President, and CEO of IonQ, emphasized Japan&#8217;s longstanding leadership in technology and noted that the new alliance has already resulted in the company&#8217;s first contract through Toyota Tsusho&#8217;s client ecosystem.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/44591436" rel="noreferrer noopener">IonQ Jumps On Amazon News, But Can It Defy Quantum Bearish Trend?</a>
&#8220;We have already signed our first local deal through Toyota Tsusho&#8217;s customer network and look forward to continuing our work in the Japanese market,&#8221; Masi said.
The collaboration is part of IonQ&#8217;s ongoing global push to expand the practical use of quantum computing solutions.
The announcement further highlights the strategic role of Toyota Tsusho, the business development arm of the Toyota Group, with an annual revenue of around $70 billion.
The firm has a track record of helping international businesses scale within Japan, and its diverse industry reach—from mobility to advanced technologies—makes it a powerful gateway for IonQ&#8217;s innovations.
Kazumi Mizukawa, General Manager of Toyota Tsusho&#8217;s Enterprise IT Department, described the agreement as a &#8220;momentous step&#8221; toward commercializing quantum computing across Japanese industries.
Over the past year, IonQ has opened the first U.S. quantum manufacturing facility, installed its first quantum computer in Europe through a partnership with QuantumBasel, and formed cooperative agreements with institutions such as AIST in Japan and the city of Busan in South Korea.
These efforts reflect IonQ&#8217;s deepening investment in the APAC region, alongside earlier partnerships with Hyundai Motors, Sungkyunkwan University, and Seoul National University.
Price Action: IONQ shares closed higher by 4.65% to $26.80&nbsp;on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44942792/tesla-q1-earnings-call-company-says-more-affordable-models-launching-this-year" target="_blank" rel="noreferrer noopener">Tesla Says More Affordable Models Launching This Year: &#8216;They Will Be Affordable And You&#8217;ll Be Able To Buy One&#8217;</a></li>
</ul>
Photo via Shutterstock

Equities

Markets

IONQ

What's Going On With IonQ Stock On Wednesday?

OSI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) has outperformed the market over the past 15 years by 3.55% on an annualized basis producing an average annual return of 13.98%. Currently, OSI Systems has a market capitalization of $3.25 billion. 
Buying $1000 In OSIS: If an investor had bought $1000 of OSIS stock 15 years ago, it would be worth $7,318.71 today based on a price of $193.58 for OSIS at the time of writing.
<h3>OSI Systems's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745442933_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OSIS

Here's How Much You Would Have Made Owning OSI Systems Stock In The Last 15 Years

First Quantum Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FM#TSX">FM</a>) reported quarterly sales of $1.19 billion which beat the analyst consensus estimate of $1.06 billion by 12.26 percent. This is a 14.86 percent increase over sales of $1.04 billion the same period last year.

TSX:FM

First Quantum Minerals Q1 Sales $1.19B Beat $1.06B Estimate

<a href="https://www.bloomberg.com/news/articles/2025-04-23/trump-orders-truck-import-probe-setting-stage-for-us-tariffs">https://www.bloomberg.com/news/articles/2025-04-23/trump-orders-truck-import-probe-setting-stage-for-us-tariffs</a>

'Trump Orders Truck Import Probe, Setting Stage for US Tariffs'- Bloomberg

Ensysce Biosciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">per data from Benzinga Pro</a>.
Ensysce Biosciences on Wednesday received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled&nbsp;Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof including both composition of matter and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">method of use claims</a>.
PF9001, the medication covered by this patent, is designed to provide a safer treatment option for opioid use disorder (OUD) by using Ensysce&#8217;s TAAP&nbsp;and MPAR&nbsp;abuse-deterrent and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/ac44946545/ensysce-biosciences-receives-u-s-patent-for-groundbreaking-treatment-of-opioid-use-disorder" rel="noreferrer noopener">overdose protection technologies</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44963467/why-is-summit-therapeutics-stock-soaring-on-wednesday" rel="noreferrer noopener">Why Is Summit Therapeutics Stock Soaring On Wednesday?</a>
Methadone has long been used for OUD, but concerns over cardiac side effects, respiratory depression, and risk of overdose have limited its use.
Ensysce has developed a new class of agents for OUD in the form of PF9001.
Data demonstrating a reduction in the potential for cardiotoxicity, validating MPAR&nbsp;overdose protection, and indications of potentially delivering a prolonged and predictable effect following once-daily dosing.
The National Institute on Drug Abuse of the National Institutes of Health supported the research covered by this patent.
Ensysce Biosciences completed Part 1 of its second clinical trial in April to evaluate PF614-MPAR <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/ac44810577/ensysce-biosciences-announces-positive-data-from-opioid-overdose-protection-study" rel="noreferrer noopener">for overdose protection</a>.
PF614-MPAR-102 demonstrated that the combined Ensysce TAAP&nbsp;and MPAR&nbsp;technologies can relieve severe pain yet protect from the risk of excessive doses when consumed accidentally or deliberately.
Part 1 of this second study of PF614-MPAR overdose protection confirmed that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.
The data showed that the maximum amount of oxycodone released from PF614-MPAR, when three or more doses were taken at one time (Cmax), was reduced compared to that released following the consumption of the same amount of PF614 alone, evidence of overdose protection.
When five doses of PF614-MPAR were administered, overdose protection was appropriately greater than that observed from three dose units.
Additionally, safety data from the trial showed no unexpected adverse events from either PF614 or PF614-MPAR.
The trial will now continue to enroll Part 2 to examine potential food effects and Part 3 to evaluate repeat dosing of PF614 vs. PF614-MPAR. The aggregate data will allow the company to focus on perfecting a final drug product to move into commercialization.
Ensysce Biosciences announced approximately $1.1 million of registered direct offering in March by issuing 315,188 shares <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44559449/ensysce-biosciences-inc-announces-1-1-million-registered-direct-offering-priced-at-the-market-und" rel="noreferrer noopener">at $3.49 per share</a>.
Price Action: ENSC stock is up 96.30% at $3.67 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44963523/rezolute-thrilled-with-positive-review-of-genetic-disorder-trial-expects-topline-results-in-december" target="_blank" rel="noreferrer noopener">Rezolute &#8216;Thrilled&#8217; With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Health Care

ENSC

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/quote/TXN">from the quarter</a>.
<ul>
<li>Q1 Revenue: $4.07 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $3.91 billion</li>
</ul>
<ul>
<li>Q1 EPS: $1.28, versus estimates of $1.07</li>
</ul>
Total revenue climbed 11% year-over-year and 2% sequentially as all markets saw a quarter-over-quarter increase with the exception of personal electronics, which the company attributed to seasonality.
Texas Instruments reported $6.2 billion in cash flow from operations over the trailing 12 months, and $1.7 billion of free cash flow over the same period. 
&#8220;History says it is important to have capacity and inventory in times like these, and we are well positioned,&#8221; the company said on a conference call with investors. 
&#8220;In addition, geopolitically dependable capacity will matter more, and it is increasingly critical and valuable to our customers. We have flexibility and are prepared to navigate the evolving supply chain dynamics.&#8221;
Related Link: <a href="https://www.benzinga.com/news/earnings/25/04/44966124/ibm-shares-slide-despite-better-than-expected-q1-details">IBM Shares Slide Despite Better-Than-Expected Q1: Details</a>
Outlook: Texas Instruments sees second-quarter revenue of $4.17 billion to $4.53 billion versus estimates of $4.13 billion. The company expects second-quarter earnings to be between $1.21 and $1.47 per share versus estimates of $1.23 per share. 
Texas Instruments noted on the conference call that it doesn&#8217;t expect any near-term impacts related to macroeconomic uncertainty. But, the company will take a cautious approach as there are &#8220;many things still changing.&#8221; Texas Instruments said it&#8217;s working with customers to understand and support their needs and is prepared for a &#8220;range of scenarios&#8221; in the second half of the year, heading into 2026.
TXN Price Action: <a href="http://benzinga.com/quote/txn">Texas Instruments shares</a> were up after-hours 5.15% at $159.99 at the time of publication on Wednesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: michelmond/Shutterstock.

After-Hours Center

Texas Instruments Q1 Earnings: Revenue Beat, EPS Beat, Strong Guidance — 'Prepared To Navigate The Evolving Supply Chain Dynamics'

NewMarket (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEU#NYSE">NEU</a>) reported quarterly earnings of $13.26 per share. This is a 18.08 percent increase over earnings of $11.23 per share from the same period last year. The company reported $700.95 million in sales this quarter. This is a 0.60 percent increase over sales of $696.74 million the same period last year.

NewMarket Q1 EPS $13.26 Up From $11.23 YoY, Sales $700.95M Up From $696.74M YoY

<h3>Gainers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares increased by 58.6% to $0.17 during Wednesday's after-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Linkage Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) shares rose 26.7% to $2.42. The company's market cap stands at $7.4 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares increased by 11.86% to $0.17. The market value of their outstanding shares is at $67.6 million. </li>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) shares increased by 10.18% to $1.19. The company's market cap stands at $30.0 million. </li>
<li>REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) stock moved upwards by 8.15% to $2.85. The company's market cap stands at $80.0 million. </li>
<li>Epsium Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) shares increased by 7.8% to $5.8. The market value of their outstanding shares is at $76.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares declined by 8.2% to $0.42 during Wednesday's after-market session. The company's market cap stands at $6.7 million. </li>
<li>Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) shares declined by 6.57% to $23.75. The market value of their outstanding shares is at $447.8 million. </li>
<li>Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) stock decreased by 5.89% to $7.92. The market value of their outstanding shares is at $672.6 million. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) shares fell 5.04% to $0.45. The company's market cap stands at $5.1 million. </li>
<li>Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) shares declined by 4.92% to $2.71. The company's market cap stands at $12.9 million. </li>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) shares declined by 4.88% to $2.66. The company's market cap stands at $66.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Airspan Networks Holdings Inc

Notizie

Ultime notizie per Airspan Networks Holdings Inc (OTC:MIMOQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO